Cargando…

Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia

BACKGROUND: Acute myeloid leukemia (AML) with antecedent hematological disease (s-AML) and treatment-related AML (t-AML) predicts poor prognosis. Intensive treatment protocols of those high-risk patients should consider allogeneic stem cell transplantation (allo-HSCT) in first complete remission (CR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleischmann, Maximilian, Schnetzke, Ulf, Frietsch, Jochen J., Sayer, Herbert G., Schrenk, Karin, Hammersen, Jakob, Glaser, Anita, Hilgendorf, Inken, Hochhaus, Andreas, Scholl, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article – Clinical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114033/ https://www.ncbi.nlm.nih.gov/pubmed/34297206 http://dx.doi.org/10.1007/s00432-021-03733-0

Ejemplares similares

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
por: Mühleck, Regina, et al.
Publicado: (2021)

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
por: Fleischmann, Maximilian, et al.
Publicado: (2022)

Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia
por: Tober, Romy, et al.
Publicado: (2022)

Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms
por: O‘Hagan Henderson, Samantha, et al.
Publicado: (2021)

A Mosquito Bite with Devastating Complications in an Immunocompromised Patient
por: Frietsch, Jochen J., et al.
Publicado: (2019)

In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation
por: Frietsch, Jochen J, et al.
Publicado: (2019)

Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity
por: Frietsch, Jochen J., et al.
Publicado: (2020)

Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma
por: Frietsch, Jochen J., et al.
Publicado: (2022)

A 19-year-old patient with atypical chronic myeloid leukemia
por: Ernst, Philipp, et al.
Publicado: (2020)

The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm
por: O’Hagan Henderson, Samantha, et al.
Publicado: (2021)

Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient
por: Voigt, Margarete, et al.
Publicado: (2021)

Isolation of Hafnia paralvei co-harbouring bla(NDM-1) and bla(VIM-1) in a woman who underwent allogeneic hematopoietic stem cell transplantation
por: Appel, Tobias Manuel, et al.
Publicado: (2023)

Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid Leukemia
por: Fischer, Mike, et al.
Publicado: (2016)

Psychosocial distress in young adults surviving hematological malignancies: a pilot study
por: Wittwer, Andreas, et al.
Publicado: (2022)

Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
por: Scholl, Sebastian, et al.
Publicado: (2020)

PB1774: PHARMACOLOGICAL STRATEGIES TO OVERCOME RESISTANCE IN AML CELL LINE MODELS HARBORING ACTIVATING FLT3-ITD AND PTPN11 MUTATIONS
por: Fleischmann, Maximilian, et al.
Publicado: (2023)

Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Detection of community‐acquired respiratory viruses in allogeneic stem‐cell transplant recipients and controls—A prospective cohort study
por: Rachow, Tobias, et al.
Publicado: (2020)

Clinical, social, and psycho-oncological needs of adolescents and young adults (AYA) versus older patients following hematopoietic stem cell transplantation
por: Pulewka, Kristin, et al.
Publicado: (2020)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders
por: Kaiser, Alexander, et al.
Publicado: (2020)

Publisher Correction: SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders
por: Kaiser, Alexander, et al.
Publicado: (2021)

Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation
por: Fuchs, Mary, et al.
Publicado: (2012)

Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia
por: Wei, Hui, et al.
Publicado: (2020)

Treating Relapsed/Refractory Acute Myeloid Leukemia with Chidamide, Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor with Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
por: Yao, Wen, et al.
Publicado: (2022)

Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study
por: Ye, Li, et al.
Publicado: (2021)

P474: FUNCTIONAL (PHOSPHO-)PROTEOMICS OF DRUG RESPONSE IN ACUTE MYELOID LEUKEMIA
por: Oliinyk, Denys, et al.
Publicado: (2023)

Intermediate-dose cytarabine is an effective therapy for adults with non-Langerhans cell histiocytosis
por: Liu, Ting, et al.
Publicado: (2022)

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
por: Galtier, Jean, et al.
Publicado: (2021)

Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation
por: Gill, Harinder, et al.
Publicado: (2020)

Staphylococcus intermedius infection with splenic abscesses in a patient with acute lymphoblastic leukemia
por: Hauptmann, Lisa, et al.
Publicado: (2023)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors
por: Schmitt, M, et al.
Publicado: (2013)

P960: EXTRAMEDULLARY MYELOMA REMAINS AN UNMET CLINICAL NEED EVEN IN THE ERA OF NOVEL AGENT. ANALYSIS OF THE SINGLE CENTER MCOHORT.
por: Brioli, Annamaria, et al.
Publicado: (2023)

Cytarabine-Induced Encephalitis
por: Lenfant, Christine, et al.
Publicado: (2021)

Rational design of a new cytarabine-based prodrug for highly efficient oral delivery of cytarabine
por: Zhang, Jing, et al.
Publicado: (2018)

Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
por: Momparler, Richard L
Publicado: (2013)

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia
por: Jost, Felix, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5fl3tjlgqnk4th2i0vnu83p3ta